SEC filing · 8-K

Caribou Biosciences, Inc.: Executive or director change

Caribou Biosciences is exploring strategic alternatives, discontinuing its CAR-T clinical programs, and cutting its workforce.

Filed October 6, 2026

Negative for the company

What happened

The Board approved a process to evaluate strategic alternatives, including a potential merger, acquisition, or sale of assets.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Caribou Biosciences, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.